Stefan Alexander Koerber1, Clara Schoneweg2, Alla Slynko3, David Krug4, Matthias F Haefner5, Klaus Herfarth6, Juergen Debus7, Florian Sterzing8, Magnus von Knebel Doeberitz9, Elena-Sophie Prigge10, Miriam Reuschenbach11. 1. Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: Stefan.Koerber@med.uni-heidelberg.de. 2. Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: clara.schoneweg@t-online.de. 3. Institute of Biostatistics, German Cancer Research Center, Heidelberg, Germany. Electronic address: a.slynko@dkfz-heidelberg.de. 4. Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: David.Krug@med.uni-heidelberg.de. 5. Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: Matthias.Haefner@med.uni-heidelberg.de. 6. Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: Klaus.Herfarth@med.uni-heidelberg.de. 7. Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: Juergen.Debus@med.uni-heidelberg.de. 8. Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: Florian.Sterzing@med.uni-heidelberg.de. 9. Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Germany. Electronic address: knebel@med.uni-heidelberg.de. 10. Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Germany. Electronic address: elena.prigge@med.uni-heidelberg.de. 11. Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Germany. Electronic address: miriam.reuschenbach@med.uni-heidelberg.de.
Abstract
BACKGROUND: The purpose of this study was to evaluate HPV-DNA and p16(INK4a) (p16) expression as prognostic markers for outcome in patients with anal cancer. METHODS: From January 2000 to December 2011 a cohort of 105 anal cancer patients was treated with definitive chemoradiation at our institution. Tumor biopsies from 90 patients were analyzed for HPV-DNA by polymerase chain reaction and for p16 expression by immunohistochemistry. RESULTS: Median follow-up was 48.6months (range 2.8-169.1months). HPV-DNA or p16-expression was found in 75 anal cancers each (83.3%), concordance was detectable in 70 tumors (77.8%). Significantly improved overall survival (OS) [77.1% vs. 51.4%, p=0.005], progression-free survival (PFS) [64.0% vs. 35.0%, p<0.001] and improved local control [81.0% vs. 55.9%, p=0.023] was found for concomitant HPV- and p16-positive anal carcinomas (cHPPAC) in univariate analysis. Multivariate analysis showed better OS [p=0.015] and PFS [p=0.002] for cHPPAC. CONCLUSION: The combination of HPV-DNA and p16 can be used as an independent prognostic parameter in anal cancer patients.
BACKGROUND: The purpose of this study was to evaluate HPV-DNA and p16(INK4a) (p16) expression as prognostic markers for outcome in patients with anal cancer. METHODS: From January 2000 to December 2011 a cohort of 105 anal cancerpatients was treated with definitive chemoradiation at our institution. Tumor biopsies from 90 patients were analyzed for HPV-DNA by polymerase chain reaction and for p16 expression by immunohistochemistry. RESULTS: Median follow-up was 48.6months (range 2.8-169.1months). HPV-DNA or p16-expression was found in 75 anal cancers each (83.3%), concordance was detectable in 70 tumors (77.8%). Significantly improved overall survival (OS) [77.1% vs. 51.4%, p=0.005], progression-free survival (PFS) [64.0% vs. 35.0%, p<0.001] and improved local control [81.0% vs. 55.9%, p=0.023] was found for concomitant HPV- and p16-positive anal carcinomas (cHPPAC) in univariate analysis. Multivariate analysis showed better OS [p=0.015] and PFS [p=0.002] for cHPPAC. CONCLUSION: The combination of HPV-DNA and p16 can be used as an independent prognostic parameter in anal cancerpatients.
Authors: Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld Journal: Nat Rev Cancer Date: 2016-03-18 Impact factor: 60.716
Authors: Grace Lee; Daniel W Kim; Vinayak Muralidhar; Devarati Mitra; Nora K Horick; Christine E Eyler; Theodore S Hong; Lorraine C Drapek; Jill N Allen; Lawrence S Blaszkowsky; Bruce Giantonio; Aparna R Parikh; David P Ryan; Jeffrey W Clark; Jennifer Y Wo Journal: Oncologist Date: 2020-09-12
Authors: Duncan C Gilbert; Eva Serup-Hansen; Dorte Linnemann; Estrid Høgdall; Charles Bailey; Jeff Summers; Hanne Havsteen; Gareth J Thomas Journal: Br J Cancer Date: 2016-01-05 Impact factor: 7.640